Pharming Group N.V.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Accelerated filer
State of Incorporation
Netherlands
Business Address
DARWINWEG 24, LEIDEN, P7, 2333 CR
Mailing Address
DARWINWEG 24, LEIDEN, P7, 2333 CR
Phone
31 (0)71 5247 400
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 6-K Foreign company current report | April 2, 2026 | View on SEC |
| 20-F Foreign company annual report | April 2, 2026 | View on SEC |
| 6-K Foreign company current report | March 27, 2026 | View on SEC |
| 6-K Foreign company current report | March 24, 2026 | View on SEC |
| 6-K Foreign company current report | March 12, 2026 | View on SEC |
| 6-K Foreign company current report | February 3, 2026 | View on SEC |
| 6-K Foreign company current report | February 2, 2026 | View on SEC |
| 6-K Foreign company current report | January 8, 2026 | View on SEC |
| 6-K Foreign company current report | November 6, 2025 | View on SEC |
| 6-K Foreign company current report | October 22, 2025 | View on SEC |
Annual Reports
20-F
April 2, 2026
- Successful launch of JOENJA, the first FDA-approved treatment for APDS, generating $34.6 million in its first year.
- Strong revenue growth of 13% year-over-year, reaching $245.1 million in 2023.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.